Prevention of diabetes
Anti-obesity drug Reduces Diabetes risks by 60%
Svetlana Maslova, Hi-tech+
Scientists have demonstrated that a recently approved anti-obesity drug in the United States is effective in preventing the development of type 2 diabetes. It is especially important that the risks were significantly reduced even in people with prediabetes.
According to a new study by scientists from the United States, the drug semaglutide reduces the risk of developing diabetes by 60%. Currently, semaglutide is approved for the treatment of obesity in the United States and may soon receive appropriate approval in the UK, writes EurekAlert.
From previous studies, scientists knew that semaglutide in combination with lifestyle correction reduces weight by an average of 15%. "This is enough to prevent a wide range of complications caused by obesity," the scientists explain. Today, obesity remains the leading risk factor for type 2 diabetes, so scientists decided to evaluate the consequences of taking semaglutide for the prevention of the disease.
Before and after treatment, the risks were assessed using the CMDS formula, which analyzes gender, age, race, body mass index, blood pressure, glucose, cholesterol and triglycerides.
In the first stage, scientists evaluated the effect of semaglutide or placebo in 1961 participants for 68 weeks (step1 group). 803 people took part in the second stage. Their semaglutide regimen was 20 weeks, and then for the next 48 weeks they were given semaglutide or placebo (step2). All the volunteers were overweight or obese.
After treatment with semaglutide, the risk of diabetes decreased by 61%. The average weight loss was 17%.
It is noteworthy that the drug reduced the risk of diabetes by the same amount both in patients with prediabetes and in volunteers without it. Meanwhile, in order to achieve the necessary results, it was important to take semaglutide for a long time, the authors specify.
"Given the growing rates of obesity and diabetes, semaglutide can be used with high efficiency to reduce the burden of both chronic diseases," concluded Timothy Garvey, the author of the work.
Portal "Eternal youth" http://vechnayamolodost.ru